Follow-On Biologics Presentation

Patients should not have to accept greater risks or uncertainties in using a follow-on product than when they use an innovator's product.
epoetin
  • Recommend
  • Tweet
  • Print
  • Email

This presentation covers:

  • BIO's Position on Follow-On Biologics
  • (FOBs)
  • Biological Products vs. Chemical “Small-Molecule” Drugs
  • Generics vs. Follow-Ons
  • Immunogenicity
  • Naming of FOBs
  • Conclusions

BIO’s Position on FOBs

Ensuring Patient Safety

  • Patients should not have to accept greater risks or uncertainties in using a follow-on product than when they use an innovator's product.
  • A clinical trial remains a fundamental principle for evaluating the safety and effectiveness of a follow-on biotechnology product

Protecting Incentives for Innovation, including Intellectual Property Rights

  • Any approval of a follow-on biologic must be carefully crafted so that it does not create disincentives to research and development of innovative biotechnology products
  • FDA cannot rely on an innovator’s unpublished proprietary data, including trade secrets, to approve a follow-on biologic

Download the presentation

Hide Date: 
Hide Date